|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
3
|
Balch CM, Gershenwald JE, Soong SJ,
Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG,
Ding S, et al: Final version of 2009 AJCC melanoma staging and
classification. J Clin Oncol. 27:6199–6206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ortega E, Marti RM, Yeramian A, Sorolla A,
Dolcet X, Llobet D, Abal L, Santacana M, Pallares J,
Llombart-Cussac A and Matias-Guiu X: Targeted therapies in
gynecologic cancers and melanoma. Semin Diagn Pathol. 25:262–273.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Terheyden P, Tilgen W and Hauschild A:
Recent aspects of medical care of malignant melanoma. J Dtsch
Dermatol Ges. 6:868–878. 2008.(In English, German). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
di Pietro A, Tosti G, Ferrucci PF and
Testori A: Oncophage: Step to the future for vaccine therapy in
melanoma. Expert Opin Biol Ther. 8:1973–1984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hou J, Zhou Y, Zheng Y, Fan J, Zhou W, Ng
IO, Sun H, Qin L, Qiu S, Lee JM, et al: Hepatic RIG-I predicts
survival and interferon-α therapeutic response in hepatocellular
carcinoma. Cancer Cell. 25:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sumantran VN, Mishra P and Sudhakar N:
Microarray analysis of differentially expressed genes regulating
lipid metabolism during melanoma progression. Indian J Biochem
Biophys. 52:125–131. 2015.PubMed/NCBI
|
|
10
|
Dadras SS, Lin RJ, Razavi G, Kawakami A,
Du J, Feige E, Milner DA, Loda MF, Granter SR, Detmar M, et al: A
novel role for microphthalmia-associated transcription
factor-regulated pigment epithelium-derived factor during melanoma
progression. Am J Pathol. 185:252–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Minca EC, Tubbs RR, Portier BP, Wang Z,
Lanigan C, Aronow ME, Triozzi PL, Singh A, Cook JR, Saunthararajah
Y, et al: Genomic microarray analysis on formalin-fixed
paraffin-embedded material for uveal melanoma prognostication.
Cancer Genet. 207:306–315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chiu CG, Nakamura Y, Chong KK, Huang SK,
Kawas NP, Triche T, Elashoff D, Kiyohara E, Irie RF, Morton DL and
Hoon DS: Genome-wide characterization of circulating tumor cells
identifies novel prognostic genomic alterations in systemic
melanoma metastasis. Clin Chem. 60:873–885. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Han B, Liu N, Yang X, Sun HB and Yang YC:
MRG1 expression in fibroblasts is regulated by Sp1/Sp3 and an Ets
transcription factor. J Biol Chem. 276:7937–7942. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yahata T, de Caestecker MP, Lechleider RJ,
Andriole S, Roberts AB, Isselbacher KJ and Shioda T: The
MSG1 non-DNA-binding transactivator binds to the p300/CBP
coactivators, enhancing their functional link to the Smad
transcription factors. J Biol Chem. 275:8825–8834. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Nair SS, Chaubal VA, Shioda T, Coser KR
and Mojamdar M: Over-expression of MSG1 transcriptional
co-activator increases melanin in B16 melanoma cells: A possible
role for MSG1 in melanogenesis. Pigment Cell Res.
14:206–209. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ahmed NU, Shioda T, Coser KR, Ichihashi M
and Ueda M: Aberrant expression of MSG1 transcriptional
activator in human malignant melanoma in vivo. Pigment Cell Res.
14:140–143. 2001.PubMed/NCBI
|
|
17
|
Hou J, Wang P, Lin L, Liu X, Ma F, An H,
Wang Z and Cao X: MicroRNA-146a feedback inhibits RIG-I-dependent
Type I IFN production in macrophages by targeting TRAF6, IRAK1, and
IRAK2. J Immunol. 183:2150–2158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Martinez-Cardús A, Vizoso M, Moran S and
Manzano JL: Epigenetic mechanisms involved in melanoma pathogenesis
and chemoresistance. Ann Transl Med. 3:2092015.PubMed/NCBI
|
|
20
|
Elder DE: Pathology of melanoma. Surg
Oncol Clin N Am. 24:229–237. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bartlett EK and Karakousis GC: Current
staging and prognostic factors in melanoma. Surg Oncol Clin N Am.
24:215–227. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Higgins HW II, Lee KC, Galan A and Leffell
DJ: Melanoma in situ: Part II. Histopathology, treatment, and
clinical management. J Am Acad Dermatol. 73:193–203. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stenzel M, Tura A, Nassar K, Rohrbach JM,
Grisanti S, Lüke M and Lüke J: Analysis of caveolin-1 and
phosphoinositol-3 kinase expression in primary uveal melanomas.
Clin Experiment Ophthalmol. 44:400–409. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Talaiezadeh A, Jalali F, Galehdari H and
Khodadadi A: Time depended Bcl-2 inhibition might be useful for a
targeted drug therapy. Cancer Cell Int. 15:1052015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mukherjee N, Schwan JV, Fujita M, Norris
DA and Shellman YG: Alternative treatments for melanoma: Targeting
BCL-2 family members to De-Bulk and kill cancer stem cells. J
Invest Dermatol. 135:2155–2161. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hartman ML and Czyz M: Pro-survival role
of MITF in melanoma. J Invest Dermatol. 135:352–358. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brazel AJ and Vernimmen D: The complexity
of epigenetic diseases. J Pathol. 238:333–344. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ambrosone CB, Hong CC and Goodwin PJ: Host
factors and risk of breast cancer recurrence: Genetic, epigenetic
and biologic factors and breast cancer outcomes. Adv Exp Med Biol.
862:143–153. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Farooqi AA, Tang JY, Li RN, Ismail M,
Chang YT, Shu CW, Yuan SS, Liu JR, Mansoor Q, Huang CJ and Chang
HW: Epigenetic mechanisms in cancer: Push and pull between kneaded
erasers and fate writers. Int J Nanomedicine. 10:3183–3191.
2015.PubMed/NCBI
|
